Online inquiry

IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13549MR)

This product GTTS-WQ13549MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets GPI-APs gene. The antibody can be applied in Benign prostatic hyperplasia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Aeromonas hydrophila
RefSeq NM_000615.7; NM_001144822.2; NM_000591.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684; 965; 929
UniProt ID P13591; P19256; P08571
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13549MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8674MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ7203MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ1510MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-011
GTTS-WQ2487MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 212
GTTS-WQ1913MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ9520MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ9895MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ976MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW